Corrie M. Marijnen

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study.

Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study.

Journal: Clinical colorectal cancer

Published: March 26, 2026

Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study.

Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study.

Journal: BMJ open

Published: December 17, 2025

NTCP models predicting bowel toxicity after total neoadjuvant treatment or chemoradiation for rectal cancer in the RAPIDO trial.

NTCP models predicting bowel toxicity after total neoadjuvant treatment or chemoradiation for rectal cancer in the RAPIDO trial.

Journal: International journal of radiation oncology, biology, physics

Published: November 26, 2025

Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.

Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.

Journal: The Lancet. Oncology

Published: November 26, 2025

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 25, 2025

Tumor-Infiltrating Lymphocytes and Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer: Insights From the Prospective PAPBI Cohort.

Tumor-Infiltrating Lymphocytes and Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer: Insights From the Prospective PAPBI Cohort.

Journal: International journal of radiation oncology, biology, physics

Published: May 20, 2025

Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial.

Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial.

Journal: The British journal of surgery

Published: May 09, 2025

ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy.

ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 16, 2025

Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy.

Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy.

Journal: Breast (Edinburgh, Scotland)

Published: February 10, 2025

From standardized to individualized margins for online adaptive tumor dose escalation in rectal cancer.

From standardized to individualized margins for online adaptive tumor dose escalation in rectal cancer.

Journal: Radiation oncology (London, England)

Published: January 15, 2025

Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial.

Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial.

Journal: BJS open

Published: January 07, 2025

Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial.

Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial.

Journal: International journal of radiation oncology, biology, physics

Published: November 13, 2024

Showing 1-12 of 135

Last Updated: 09/26/2026